Pricing

Lineage Cell Therapeutics, Inc. (LCTX)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Brian M. Culley
Employees:
60
2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008
5105213390
OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, are in clinical trials to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available